Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 48.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 204,205 shares of the company's stock after purchasing an additional 66,662 shares during the quarter. Victory Capital Management Inc. owned approximately 0.20% of Neurocrine Biosciences worth $23,529,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at approximately $28,000. Innealta Capital LLC acquired a new position in shares of Neurocrine Biosciences in the 2nd quarter valued at $30,000. New Covenant Trust Company N.A. purchased a new position in Neurocrine Biosciences in the 1st quarter worth $32,000. EdgeRock Capital LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter valued at about $35,000. Finally, Blue Trust Inc. grew its stake in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company's stock valued at $40,000 after purchasing an additional 220 shares during the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. StockNews.com downgraded Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Friday, November 1st. Jefferies Financial Group increased their price objective on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a "buy" rating in a research note on Monday, August 19th. Citigroup boosted their target price on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the company a "neutral" rating in a research report on Friday, August 2nd. Royal Bank of Canada cut their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research report on Friday, October 4th. Finally, Guggenheim boosted their price objective on Neurocrine Biosciences from $170.00 to $180.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Price Performance

NBIX traded up $1.51 during trading hours on Tuesday, reaching $119.13. The company's stock had a trading volume of 1,092,808 shares, compared to its average volume of 868,996. The stock has a market cap of $12.06 billion, a PE ratio of 31.60 and a beta of 0.35. Neurocrine Biosciences, Inc. has a fifty-two week low of $108.14 and a fifty-two week high of $157.98. The business's 50-day moving average is $118.44 and its 200-day moving average is $132.40.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.